These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26184481)

  • 1. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
    Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
    Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
    Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
    Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.
    Capone E; Piccolo E; Fichera I; Ciufici P; Barcaroli D; Sala A; De Laurenzi V; Iacobelli V; Iacobelli S; Sala G
    Oncotarget; 2017 Sep; 8(36):60368-60377. PubMed ID: 28947977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endosialin: a novel malignant cell therapeutic target for neuroblastoma.
    Rouleau C; Smale R; Sancho J; Fu YS; Kurtzberg L; Weber W; Kruger A; Jones C; Roth S; Bormann C; Dunham S; Krumbholz R; Curiel M; Wallar G; Mascarello J; Campos-Rivera J; Horten B; Schmid S; Miller G; Teicher BA
    Int J Oncol; 2011 Oct; 39(4):841-51. PubMed ID: 21701770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
    Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
    Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
    Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
    Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
    Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
    Rouleau C; Smale R; Fu YS; Hui G; Wang F; Hutto E; Fogle R; Jones CM; Krumbholz R; Roth S; Curiel M; Ren Y; Bagley RG; Wallar G; Miller G; Schmid S; Horten B; Teicher BA
    Int J Oncol; 2011 Jul; 39(1):73-89. PubMed ID: 21537839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.